or Try an Advanced Search...

    Technical Analysis for DVAX - Dynavax Technologies Corporation

    Grade Last Price % Change Price Change
    F 11.16 -0.62% -0.07
    DVAX closed down 0.62 percent on Monday, July 1, 2024, on 59 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical DVAX trend table...
    Date Alert Name Type % Chg
    Shooting Star Candlestick Bearish 0.00%
    Doji - Bearish? Reversal 0.00%
    Outside Day Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Oversold Stochastic Weakness -0.62%
    Stochastic Buy Signal Bullish -1.85%
    Pocket Pivot Bullish Swing Setup -1.85%
    Lower Bollinger Band Walk Weakness -1.85%
    Lower Bollinger Band Touch Weakness -1.85%
    Oversold Stochastic Weakness -1.85%
    Older End-of-Day Signals for DVAX ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Resistance about 9 hours ago
    Rose Above Previous Day's High about 10 hours ago
    Outside Day about 10 hours ago
    Up 2% about 10 hours ago
    Up 1% about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    DVAX Chart by TradingView
    Basic chart:

    Profile

    Dynavax Technologies Corporation Description

    Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Inflammatory Diseases Hepatitis B Asthma Chronic Obstructive Pulmonary Disease Pulmonary Disease Autoimmune And Inflammatory Disease Novel Products Tlr7 Tlr9

    Is DVAX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 28 Dynavax doses first subject in Phase I/II shingles vaccine trial
    Jun 27 Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
    Jun 11 Dynavax, Bloomin' Brands, and Premier are the most shorted small-cap stock in May - Hazeltree report
    May 28 Dynavax to Present at Upcoming Investor Conferences
    May 14 FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients
    May 14 Dynavax down 5% on FDA Complete Response Letter for Heplisav-B for hemodialysis
    May 14 UPDATE 1-US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
    May 14 Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
    May 11 Analysts Are Updating Their Dynavax Technologies Corporation (NASDAQ:DVAX) Estimates After Its First-Quarter Results
    May 10 Dynavax Technologies Corp (DVAX) Q1 2024 Earnings: Aligns with EPS Projections, Surpasses ...
    See more DVAX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.15
    52 Week Low 10.48
    Average Volume 2,374,111
    200-Day Moving Average 12.92
    50-Day Moving Average 11.55
    20-Day Moving Average 11.67
    10-Day Moving Average 11.27
    Average True Range 0.36
    RSI (14) 41.18
    ADX 15.2
    +DI 21.21
    -DI 25.26
    Chandelier Exit (Long, 3 ATRs) 11.79
    Chandelier Exit (Short, 3 ATRs) 11.98
    Upper Bollinger Bands 12.53
    Lower Bollinger Band 10.81
    Percent B (%b) 0.2
    BandWidth 14.72
    MACD Line -0.14
    MACD Signal Line -0.08
    MACD Histogram -0.0619
    Fundamentals Value
    Market Cap 1.44 Billion
    Num Shares 129 Million
    EPS 0.41
    Price-to-Earnings (P/E) Ratio 27.22
    Price-to-Sales 4.63
    Price-to-Book 2.76
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.77
    Resistance 3 (R3) 11.81 11.64 11.67
    Resistance 2 (R2) 11.64 11.49 11.62 11.63
    Resistance 1 (R1) 11.40 11.39 11.32 11.36 11.60
    Pivot Point 11.24 11.24 11.20 11.22 11.24
    Support 1 (S1) 11.00 11.08 10.92 10.96 10.72
    Support 2 (S2) 10.83 10.99 10.81 10.69
    Support 3 (S3) 10.59 10.83 10.65
    Support 4 (S4) 10.55